Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27362062 | 0.82 | PIK3CD (0.43) | NOTUMPIK3CDPIK3R1MTORLMNA | |
| SCHEMBL17050420 | 0.78 | MAOB (0.38) | NOTUMPIK3CDPIK3R1MTORMAPT | |
| SCHEMBL31290018 | 0.78 | NOTUM (0.50) | NOTUMLMNASCN1ASCN5ASCN9A | |
| SCHEMBL18227140 | 0.77 | TERT (0.48) | GAAMAPTSMN1; SMN2KDM4E | |
| SCHEMBL8600452 | 0.77 | PIK3CD (0.38) | NOTUMPIK3CDPIK3R1MTORSCN1A | |
| SCHEMBL520359 | 0.76 | CYP11B2 (0.53) | CYP11B1CYP11B2ATAD2PDE3BPDE3A | |
| SCHEMBL31481226 | 0.76 | CYP11B2 (0.53) | CYP11B1CYP11B2ATAD2PDE3BPDE3A | |
| SCHEMBL17708315 | 0.75 | CHRM1 (0.41) | ATAD2CYP19A1 | |
| SCHEMBL3041759 | 0.74 | MAOA (0.47) | — | |
| SCHEMBL20868003 | 0.73 | CHRNB4 (0.36) | GAAMAPTMAPK14ATAD2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180289718-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-10-11 | — | — | US | disclosed |
| US-10016439-B2 | Fused imidazole compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-3099672-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO Pharmaceutical Co., Ltd. (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| WO-2015115673-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289718-A1 | FUSED IMIDAZOLE COMPOUNDS | GABRA5, CHRNA5, GABRP | NOTUM 1870/4885PIK3CD 856/4885PIK3R1 1066/4885 |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | GABRA5, CHRNA5, GABRP | NOTUM 1870/4885PIK3CD 856/4885PIK3R1 1066/4885 |
| US-10016439-B2 | Fused imidazole compounds | GABRA5, CHRNA5, GABRP | NOTUM 1870/4885PIK3CD 856/4885PIK3R1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.